GlassScriptPhysician profile
Mark J Butler
NPI 1396847984
$8,290.03
in general payments reported to CMS, 2019-2025
51 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $733 · 2021: $907 · 2022: $1,343 · 2023: $1,137 · 2024: $1,317 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,643 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,643.19 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,418.47 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $671.21 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $582.29 | 2024 | |
| Amgen INC. | $574.87 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $520.54 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $490.55 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $420.16 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $378.82 | 2022-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $312.57 | 2019-2020 | |
| Abbott Laboratories | $247.20 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $203.21 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $187.40 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $184.21 | 2019-2025 | Invega Sustenna, Spravato |
| Kowa Pharmaceuticals America, INC. | $182.32 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $179.91 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.